Hutchinson Cancer Center leads large-scale review of COVID-19 clinical trials that highlights multiple disparities
On Dec. 5, 2022, the Fred Hutchinson Cancer Center announced that according to a new meta-analysis women were…
On Dec. 5, 2022, the Fred Hutchinson Cancer Center announced that according to a new meta-analysis women were…
On Dec. 5, 2022, Pfizer and BioNTech announced that the companies had submitted an application to the U.S….
On Dec. 2, 2022, the Oregon Department of Agriculture (ODA) and the U.S. Department of Agriculture’s (USDA) Animal…
On Dec. 2, 2022, in a multi-center collaboration led by Scripps Research, scientists announced they have achieved promising…
On Nov. 29, 2022, Novavax announced that the World Health Organization had issued an updated Emergency Use Listing…
On Nov. 21, 2022, the WHO is launching a global scientific process to update the list of priority…
On Nov. 18, 2022, Pfizer and BioNTech announced results from an analysis examining the immune response induced by…
On Nov. 18, 2022, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid (COVID-19 Vaccine (Recombinant…
On Nov. 18, 2022, the World Health Organisation for Animal Health (WHO) announced that Peru had reported its…
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
On Nov. 16, 2022, the Cancer Prevention and Research Institute of Texas (CPRIT) approved $12 million in recruitment…
On Nov. 14, 2022, Moderna announced that both of Moderna’s bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger…
On Nov. 10, 2022, Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
On Nov. 9, 2022, researchers at the University of Missouri announced they had identified the highly prevalent, specific…
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…
On Nov. 5, 2022, the U.S. Department of Agriculture’s (USDA) Animal Plant Health Inspection Service (APHIS) confirmed the…
On Nov. 4, 2022, Moderna announced that Health Canada had authorized the use of its BA.4/BA.5 Omicron-targeting bivalent…
On Nov. 4, 2022, Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a…
On Nov. 1, 2022, Pfizer announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal…
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
On Oct. 27, 2022, Inovio Pharma announced that it has discontinued its internally funded efforts to develop INO-4800…
On Oct. 25, 2022, Pacific Northwest National Laboratory (PNNL) announced that scientists have shown that they can detect…
On Oct. 20, 2022, the National Institutes of Health announced that a three-dose course of the hepatitis B…
On Oct. 19, 2022, the U.S. Food and Drug Administration (FDA) recommended the use of the Novavax COVID-19…
On Oct. 19, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Oct. 19, 2022, Moderna announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after…
On Oct. 19, 2022, Pfizer and BioNTech announced that the European Medicines Agencyメs (EMA) Committee for Medicinal Products…
On Oct. 18, 2022, global leaders confirmed US$ 2.6 billion in funding toward the Global Polio Eradication Initiative’s…
On Oct. 17, 2022, Moderna and Gavi, the Vaccine Alliance, announced they had mutually agreed to cancel remaining…